Aortic valve disease 3 (AOVD3): disease-characteristics research report

Aortic valve disease 3 (AOVD3; MONDO:0032783; OMIM:618496) is a proposed autosomal-dominant, ROBO4-associated cardiovascular disorder. Its reported manifestations include bicuspid aortic valve (BAV), aortic valve stenosis, aneurysm of the aortic root or ascending aorta, and, in one family, atrial septal defect. The principal evidence is a 2019 study of two families supported by cell and animal experiments. The gene–disease association should not be entered as unequivocally established: a GenCC submission classifies ROBO4–AOVD3 evidence as limited, and interpretation of at least one original familial variant remains disputed. [3][31][47][46]

Evidence notation used below: human denotes patient, family, or cohort observations; experimental denotes cultured-cell or animal findings; inference denotes a plausible link not directly established for AOVD3. PMID-linked primary articles are identified alongside citations. General BAV data are explicitly distinguished from ROBO4-specific data.

1. Disease information and identifiers

This report synthesizes aggregated disease resources and published research, not individual-level electronic health records. Published family descriptions and tissue experiments originate from individual participants, but they do not constitute a population registry. OMIM’s concise description is: “Aortic valve disease-3 (AOVD3) is characterized by aortic stenosis and/or bicuspid aortic valve (BAV), associated in some patients with aneurysm of the aortic root and/or ascending aorta.” [3][31]

Principal primary source: Gould and colleagues, Nature Genetics 51:42–50 (published online November 19, 2018; January 2019 issue), PMID:30455415, DOI 10.1038/s41588-018-0265-y, https://pubmed.ncbi.nlm.nih.gov/30455415/. Its abstract states: “we report the identification of variants in ROBO4 … that segregate with disease in two families.” [32][31]

2. Etiology: causes, risks, protection, and interactions

Proposed initiating cause. Heterozygous germline ROBO4 variants are the defining genetic hypothesis for AOVD3. In the original families, one variant disrupts exon-13 splicing; another changes the extracellular receptor residue Arg64. The phenotype is not synonymous with every case of BAV: BAV has many genetic and non-genetic contributors, and current ROBO4 evidence does not justify assigning AOVD3 to a person solely because BAV is present. [31][3][47][84]

Gene–environment interaction: The family study suggests that unidentified genetic and/or environmental influences may affect penetrance, but it did not measure a particular exposure–ROBO4 interaction. A 2024 study shows how inflammation can expose another ROBO4-dependent endothelial response; extrapolating that response to aortic-valve progression remains an inference, not a demonstrated AOVD3 mechanism. Experimental; PMID:38762541. [31][107]

3. Phenotypes

The table separates observed AOVD3-family findings from HPO terms indexed to the condition. Denominators below describe the reported families, not validated disease-wide frequencies. Typical symptom-onset ages, quantitative severity distributions, and phenotype-specific quality-of-life scores have not been established for AOVD3. A congenital valve shape can remain clinically silent until later dysfunction; aneurysm may likewise be detected by imaging before symptoms. Human; PMID:30455415. [31][73]

Valve thickening/fibroproliferation and medial elastic-fiber abnormalities were pathology findings in studied tissue, not measured population phenotypes. No reproducible AOVD3-specific behavioral, psychiatric, biochemical-laboratory, EQ-5D, SF-36, or PROMIS phenotype has been reported. Human; PMID:30455415. [31]

4. Genetic and molecular information

Gene annotation: ROBO4 (roundabout guidance receptor 4), HGNC:17985, NCBI Gene:54538, OMIM:607528, UniProt:Q8WZ75, chromosome 11q24.2. Its encoded endothelial-associated receptor is the proposed affected protein. The familial findings are germline, not tumor-acquired somatic variants. Human and experimental; PMID:30455415. [61][3][31]

The study found filtered rare ROBO4 variants in 13/736 probands (1.77%), versus one variant among 376 controls (P=0.0432). That is an enrichment in a selected BAV/ascending-aneurysm cohort, neither AOVD3 prevalence nor the diagnostic yield of ROBO4 testing in an unselected population. Human; PMID:30455415. [3][31]

Updated evidence: In a separate early-complication cohort, ROBO4 had three candidate variants among 63 probands (gene-level comparison P=0.062); variants were not significantly enriched among the 60 BAV-plus-heritable-aortic-disease probands. Human; Musfee et al., 2020, PMID:32748548, https://pubmed.ncbi.nlm.nih.gov/32748548/. A peer-reviewed 2024 exome analysis of 215 early-onset BAV families identified one predicted ROBO4 loss-of-function variant; it did not establish variant-specific AOVD3 penetrance. Human; Mansoorshahi et al., published online September 2, 2024, PMID:39226896, https://pmc.ncbi.nlm.nih.gov/articles/PMC11480851/. [34][301][110][108]

No AOVD3-specific validated modifier gene, epigenetic signature, recurrent chromosomal rearrangement, or somatic mutation was established in these sources. Other BAV-associated genes are important for the differential diagnosis, not automatically genes causing the OMIM-defined ROBO4 subtype. [31][110][21]

5. Environmental information

AOVD3 is not an infectious or zoonotic condition, and no pathogen, toxin, occupational exposure, radiation dose, diet, smoking exposure, or alcohol intake has been demonstrated to initiate the ROBO4-defined disorder. Hypertension and smoking remain clinically actionable general aortic-disease risks; controlling them should not be represented as reversing a congenital valve malformation. The 2022 ACC/AHA aortic guideline recommends treatment of hypertension in patients with thoracic aortic aneurysm and smoking-cessation efforts in those who smoke. [31][21]

6. Mechanism and pathophysiology

Ordered causal chain

1. Heterozygous ROBO4 sequence variation leads to altered ROBO4 transcript or receptor structure: exon-13 skipping is demonstrated for c.2056+1G>T; p.Arg64Cys changes an extracellular immunoglobulin-like domain. Human; PMID:30455415. [31]
2. Reduced or altered ROBO4 activity leads to weaker endothelial junctions and barrier function: ROBO4 silencing or mutant expression reduced CDH5/VE-cadherin and TJP1 and increased dextran passage across cultured aortic-endothelial monolayers. In vitro; PMID:30455415. [31]
3. Barrier disruption leads to a more invasive, mesenchymal-like endothelial state: cultured cells became elongated, expressed more SNAI1 and α-smooth-muscle actin, and invaded more readily. This is evidence suggestive of EndMT, not proof that every human lesion undergoes complete lineage conversion. In vitro; PMID:30455415. [31]
4. Branch A — developing valve: altered endocardial/endothelial behavior is inferred to lead to abnormal valve formation, including BAV; ROBO4 is expressed in developing mouse endocardial cushions, and deficient mice develop valve anomalies. Direct observation of the entire developmental chain in a human embryo is not available. Experimental plus inference; PMID:30455415. [31]
5. Branch B — aortic wall: impaired endothelial barrier and mesenchymal-like remodeling are inferred to lead to albumin entry, intimal fibrosis, collagen accumulation, and medial elastin disorganization. These downstream abnormalities were observed in one patient’s aneurysmal tissue; their precise order was not experimentally established in that patient. Human plus inference; PMID:30455415. [31]
6. Abnormal valve geometry and/or aortic-wall remodeling results in stenosis or other valve dysfunction and aortic-root/ascending-aortic aneurysm; consequent ventricular pressure load or future dissection risk is a clinical extrapolation when applied to an individual AOVD3 carrier. Human/experimental/inference; PMID:30455415. [3][31][21]

Upstream versus downstream. The receptor and endothelial-junction abnormalities are upstream hypotheses; fibroproliferation, elastin damage, altered valve flow, and aneurysm are downstream findings. In the studied aneurysmal aorta, investigators observed diminished endothelial ROBO4 staining, albumin beyond the endothelial surface, collagen-rich intimal/superficial-medial remodeling, and fragmented elastic fibers. These are more direct disease-tissue observations than any proposed named signaling cascade. Human; PMID:30455415. [31]

Relevant 2024 research, with strict disease boundaries. In irradiated bone-marrow endothelial-cell experiments, ROBO4 depletion augmented endoglin/SMAD, PI3K–AKT–mTOR, and NF-κB-associated responses. Experimental; PMID:38383474, published February 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC10881562/. These pathways must not be entered as demonstrated AOVD3-valve pathways. In another 2024 study, endothelial ROBO4 promoted TRAF7-associated IQGAP1 ubiquitination, limited prolonged RAC1 signaling and PTGS2/COX-2 expression, and restrained inflammatory permeability. Its human endothelial RNA-seq experiment is deposited as GEO:GSE231460; it did not test AOVD3 valves. Experimental; PMID:38762541, published May 18, 2024, https://pubmed.ncbi.nlm.nih.gov/38762541/. No AOVD3-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or CRISPR-screen signature was verified. [77][107]

7. Anatomical structures affected

8. Temporal development

BAV and ASD are congenital structural abnormalities; clinically important stenosis or aneurysm may become evident later. The small published AOVD3 families do not establish a median diagnosis age, annual aortic-growth rate, time to valve replacement, or age-specific penetrance. The practical course is therefore potentially lifelong and variably progressive, rather than a proven fixed-stage syndrome. There is no demonstrated spontaneous remission of a congenital BAV or established aneurysm. Human; PMID:30455415. [3][31]

For context only, a general prospective BAV cohort cited by the aortic guideline had mean ascending-aortic growth of 0.47 mm/year over 4.8 years; those figures cannot be assigned to ROBO4 carriers. The key intervention windows are identification of familial structural disease before complications and surveillance while aortic size, growth, and valve severity still permit planned treatment. [21]

9. Inheritance and population

10. Diagnostics and screening

Clinical diagnosis starts with anatomy and physiology, not a ROBO4 result. Transthoracic echocardiography (TTE) assesses cusp morphology, stenosis/regurgitation, aortic root and ascending-aortic size, and associated defects. Obtain appropriately gated CT or MRI when echocardiography cannot adequately define the thoracic aorta. ECG, symptom assessment, exercise testing in selected valve patients, and BNP when clinically appropriate address functional impact or intervention timing; none is an AOVD3-specific molecular biomarker. Aneurysmal-tissue histology can reveal remodeling but is not a routine diagnostic biopsy. [21][276][31]

Differential diagnosis: other familial BAV etiologies, syndromic or nonsyndromic heritable thoracic-aortic disease, isolated congenital BAV, and acquired calcific or rheumatic valve disease. Phenotype, family history, aortic imaging, and carefully interpreted molecular findings distinguish them; a VUS must not direct cascade testing or aortic surgery. There is no AOVD3 population newborn-screening program. [21][46][47]

11. Outcomes and prognosis

No AOVD3-specific survival curve, five- or ten-year survival percentage, life-expectancy estimate, mortality rate, validated prognostic biomarker, or patient-reported quality-of-life series was found. In the original family 1, three members had undergone aortic valve replacement, demonstrating substantial morbidity in some carriers but not a treatment rate for all AOVD3 patients. Human; PMID:30455415. [3]

Risk assessment must instead use the observed valve and aortic phenotype: severity of stenosis or regurgitation, symptoms and ventricular function, aortic diameter and growth, family dissection history, and relevant coarctation or root phenotype. Even after isolated valve replacement, patients with BAV-related aortopathy can experience later aortic events; lifelong surveillance may be necessary. General BAV outcome statistics are not ROBO4-specific prognostic estimates. [21][276]

12. Treatment and real-world implementation

No drug, gene therapy, RNA therapy, cell therapy, or immunotherapy has been shown to correct the ROBO4 defect or prevent AOVD3 itself. Care follows the measured valve and aortic abnormalities through a cardiology/valve-and-aorta team; the intervention names below are suggested NCIT search labels, not asserted NCIT codes. [21][47]

Surgical and transcatheter procedures have material general risks, including procedural complications and later prosthesis-related follow-up; the reviewed evidence supplies no AOVD3-stratified response or adverse-event rate. No verified AOVD3-specific interventional trial or NCT identifier supports an experimental treatment recommendation. [21][31]

13. Prevention

Primary prevention of an inherited valve malformation is not established. No vaccine or antimicrobial prophylaxis prevents AOVD3, and no proven protective allele or lifestyle regimen prevents transmission or congenital BAV. Genetic counseling can discuss the proposed dominant inheritance and reproductive options without presenting an unvalidated variant as predictive. [3][47][21]

Secondary prevention consists of imaging the affected person and appropriately screening at-risk first-degree relatives, then following valve severity and aortic size. Tertiary prevention consists of BP control, smoking cessation when relevant, planned intervention when guideline criteria are met, and continued post-intervention aortic imaging. There is no AOVD3-specific population or newborn-screening program; this is targeted clinical and family surveillance. [21]

14. Other species and naturally occurring disease

There is no infectious agent, animal-to-human transmission, or zoonotic potential for the genetic AOVD3 hypothesis. [31]

15. Model organisms and experimental systems

Knowledge-base conclusion: Record AOVD3 as an autosomal-dominant-pattern, incompletely penetrant ROBO4-associated disease hypothesis with limited curated gene–disease validity. The strongest disease-specific causal path is altered ROBO4 → impaired endothelial barrier/mesenchymal-like behavior → abnormal valve development and aortic-wall remodeling, with the middle cellular steps experimentally supported and several links to the full human phenotype still inferred. Do not import general BAV incidence, prognosis, intervention response, or 2024 non-valvular ROBO4 pathways as if they were measured specifically in AOVD3. [47][31][46][110][107]

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM, Gene, PMIDs, MGI.

21 of 31 terms resolved to a current term; the rest could not be looked up either way.